CAM
ANIK icon

Cresset Asset Management’s Anika Therapeutics ANIK Stock Holding History

Cresset Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-29
Closed -$1K – 540
2019
Q1 		$1K Buy
29
+5
+21% +$171 ﹤0.01% 1754
2018
Q4 		$1K Buy
+24
New +$866 ﹤0.01% 1454

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cresset Asset Management's ANIK Position: Q2 2019 in Review

Cresset Asset Management sold out of Anika Therapeutics (ANIK) in Q2 2019, closing a stake of 29 shares — an estimated $1K sold.

Cresset Asset Management first reported a position in ANIK in Q4 2018 and held it in 2 quarters. The position peaked at $1K in Q1 2019. 165 funds tracked by Wall St. Rank hold ANIK as of Q2 2019.

  • Cresset Asset Management reported no remaining Anika Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Cresset Asset Management sold 29 Anika Therapeutics shares in Q2 2019, an estimated $1K.
  • Cresset Asset Management first reported a position in Anika Therapeutics in Q4 2018 and held it in 2 quarters.
  • Cresset Asset Management's Anika Therapeutics position peaked at $1K in Q1 2019.
  • 165 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2019.

Based on Cresset Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.